AbCellera Biologics price to free cash flow ABCL

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 35.9×; Jul 2023
Peer median: 29.0×

AbCellera Biologics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2023, at 35.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	35.9×	9.4×	36.6×
2022	17.9×	9.1×	25.0×

Against its peers

Companies in Drug Manufacturers - General nearest AbCellera Biologics' size, closest first, today.

Company	Price to free cash flow
ABCLAbCellera Biologics	n/m
OGNOrganon	6.4×
LQDALiquidia	25.3×
ARQTArcutis Biotherapeutics	100×
INDVIndivior Pharmaceuticals	n/m
NRIXNurix Therapeutics	7.5×
PBHPrestige Consumer Healthcare	9.6×
KNSAKiniksa Pharmaceuticals International	32.7×
LGNDLigand Pharmaceuticals	46.0×
HRMYHarmony Biosciences	n/m
AMRXAmneal Pharmaceuticals	50.9×
Peer median	29.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on AbCellera Biologics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.